Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Biomagnetic Technologies, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Biomagnetic Technologies, Inc.: Sale of 5.5 mil. shares of common stock to foreign investors raises $2.8 mil. Dassesta International was the largest investor, acquring 4 mil. shares for $2 mil. The proceeds are intended primarily for debt repayment and working capital. The San Diego-based magnetic source imaging equipment firm "is currently in the process of seeking additional substantial equity capital from foreign investors to continue its operations beyond the end of February 1998, at which time its existing cash resources may be exhausted, precluding the company's ability to continue operations," VP-Finance Henry Bergman explains. Fiscal 1997 (ended Sept. 30) results include sales of $10.6 mil. versus $733,000 last year and a net loss of $5.2 mil. compared to $15.6 mil. in the prior year. The results reflect the fact that shipments of the firm's Magnes 2500 whole head system, "which had been delayed from fiscal year 1996, have been installed and accepted in Europe, Japan and the United States," the firm states...

You may also be interested in...



AAM Criticizes Lower Health Care Costs Act

Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.

USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

UsernamePublicRestriction

Register

MT009455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel